<b>Conclusions</b>: CLDN18.2 expression may represent a clinically relevant prognostic biomarker reflecting aggressive tumor biology in locally advanced gastric cancer treated with neoadjuvant therapy. This evidence concerns the gene CLDN18 and gastric cancer.